Truist lowered the firm’s price target on Elevance Health (ELV) to $390 from $400 and keeps a Buy rating on the shares. The firm is adjusting its model after the company’s Q4 results and 2026 guidance, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health price target raised to $397 from $394 at JPMorgan
- Elevance Health price target lowered to $409 from $431 at Bernstein
- Elevance Health price target lowered to $391 from $424 at Wells Fargo
- Elevance Health price target lowered to $393 from $404 at Barclays
- Elevance Health price target lowered to $400 from $425 at UBS